FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402777> ?p ?o ?g. }

• W4308402777 abstract "<h3>Background</h3> S-488210/S-488211 is a cancer peptide vaccine composed of 5 human leukocyte antigen (HLA)-A*02:01-restricted epitope peptides derived from 5 cancer-testis antigens: DEPDC1, MPHOSPH1, URLC10, CDCA1 and KOC1. These antigens were shown to be highly and differentially expressed in a range of solid tumours. A vaccine composed of HLA-A*24:02 restricted epitopes of the same antigens previously demonstrated safety and immunogenicity. This study aimed to evaluate the safety and immunological responses of S-488210/S-488211 in patients with HLA-A*02:01, the most prevalent HLA subtype in Europe and the US. <h3>Methods</h3> An open-label, single centre, first-in-human phase I study (NCT04316689) was conducted. Eligible patients had unresectable recurrent or metastatic malignancies of the lung, oesophagus, mesothelium, head and neck or urinary tract and had exhausted conventional treatment options. Patients who were HLA-A*02:01 positive, performance status 0-1 and had a lymphocyte count ³10% received S-488210/S-488211 (1 mg of each of 5 peptides mixed with Montanide ISA 51 VG) subcutaneously weekly for 4 weeks, then every 2 weeks for up to 8 weeks. The primary objective was to evaluate the safety and tolerability with adverse events classified by CTCAE version 4.03. The secondary objective was to evaluate cytotoxic T lymphocyte (CTL) induction rate during treatment, defined as the proportion of patients who showed increased CTL activity for ≥1 peptide. An exploratory objective was to assess disease control rate (DCR; CR+PR+SD) at 12 weeks. <h3>Results</h3> 7 patients were enrolled between 30/7/19 and 9/7/21. One patient did not receive treatment due to a decline in performance status and was excluded from the safety analysis. Median age was 57, 5/6 patients were male and 5/6 were white. All patients experienced at least 1 adverse event (AE), most commonly a Grade 1 injection site reaction. There were 2 Grade 3 treatment-related AEs (hypertension and injection site reaction), neither of which met the dose-limiting toxicity criteria. There were no treatment-related serious AEs. 3/6 patients received the full planned treatment (9 doses) and 3/6 patients were withdrawn due to disease progression or death. The CTL induction rate was 100% in the 5 evaluable patients and was highest for the DEPDC1 (100%), MPHOSPH1 (60%) and URLC10 (40%) peptides. The DCR at 12 weeks was 16.7% (1/6 patients with SD). <h3>Conclusions</h3> S-488210/S-488211 was generally well tolerated and led to a robust CTL response in a range of solid tumours. S-488210/S-488211 is being taken forward in a phase 2 study in combination with PD-L1 blockade. <h3>Acknowledgements</h3> Ricky Yang and Chi Yee Chung provided and cared for study patients <h3>Trial Registration</h3> NCT04316689 <h3>Ethics Approval</h3> The study was approved by Ethical Committee on Clinical Trial of Shionogi (held on 27 Oct 2018)" @default.
• W4308402777 created "2022-11-11" @default.
• W4308402777 creator A5007744903 @default.
• W4308402777 creator A5008796630 @default.
• W4308402777 creator A5011258855 @default.
• W4308402777 creator A5015428908 @default.
• W4308402777 creator A5029987103 @default.
• W4308402777 creator A5037248121 @default.
• W4308402777 creator A5038108842 @default.
• W4308402777 creator A5041321712 @default.
• W4308402777 creator A5051179100 @default.
• W4308402777 creator A5053669695 @default.
• W4308402777 date "2022-11-01" @default.
• W4308402777 modified "2023-09-25" @default.
• W4308402777 title "598 First in human study of S-488210/S-488211, a cancer peptide vaccine, in patients with advanced solid tumours" @default.
• W4308402777 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0598" @default.
• W4308402777 hasPublicationYear "2022" @default.
• W4308402777 type Work @default.
• W4308402777 citedByCount "0" @default.
• W4308402777 crossrefType "proceedings-article" @default.
• W4308402777 hasAuthorship W4308402777A5007744903 @default.
• W4308402777 hasAuthorship W4308402777A5008796630 @default.
• W4308402777 hasAuthorship W4308402777A5011258855 @default.
• W4308402777 hasAuthorship W4308402777A5015428908 @default.
• W4308402777 hasAuthorship W4308402777A5029987103 @default.
• W4308402777 hasAuthorship W4308402777A5037248121 @default.
• W4308402777 hasAuthorship W4308402777A5038108842 @default.
• W4308402777 hasAuthorship W4308402777A5041321712 @default.
• W4308402777 hasAuthorship W4308402777A5051179100 @default.
• W4308402777 hasAuthorship W4308402777A5053669695 @default.
• W4308402777 hasBestOaLocation W43084027771 @default.
• W4308402777 hasConcept C121608353 @default.
• W4308402777 hasConcept C126322002 @default.
• W4308402777 hasConcept C143998085 @default.
• W4308402777 hasConcept C147483822 @default.
• W4308402777 hasConcept C147969180 @default.
• W4308402777 hasConcept C154317977 @default.
• W4308402777 hasConcept C167672396 @default.
• W4308402777 hasConcept C195616568 @default.
• W4308402777 hasConcept C197934379 @default.
• W4308402777 hasConcept C202751555 @default.
• W4308402777 hasConcept C203014093 @default.
• W4308402777 hasConcept C2776789287 @default.
• W4308402777 hasConcept C2777701055 @default.
• W4308402777 hasConcept C2778375690 @default.
• W4308402777 hasConcept C2778378633 @default.
• W4308402777 hasConcept C2780868878 @default.
• W4308402777 hasConcept C55493867 @default.
• W4308402777 hasConcept C71924100 @default.
• W4308402777 hasConcept C86803240 @default.
• W4308402777 hasConcept C90924648 @default.
• W4308402777 hasConceptScore W4308402777C121608353 @default.
• W4308402777 hasConceptScore W4308402777C126322002 @default.
• W4308402777 hasConceptScore W4308402777C143998085 @default.
• W4308402777 hasConceptScore W4308402777C147483822 @default.
• W4308402777 hasConceptScore W4308402777C147969180 @default.
• W4308402777 hasConceptScore W4308402777C154317977 @default.
• W4308402777 hasConceptScore W4308402777C167672396 @default.
• W4308402777 hasConceptScore W4308402777C195616568 @default.
• W4308402777 hasConceptScore W4308402777C197934379 @default.
• W4308402777 hasConceptScore W4308402777C202751555 @default.
• W4308402777 hasConceptScore W4308402777C203014093 @default.
• W4308402777 hasConceptScore W4308402777C2776789287 @default.
• W4308402777 hasConceptScore W4308402777C2777701055 @default.
• W4308402777 hasConceptScore W4308402777C2778375690 @default.
• W4308402777 hasConceptScore W4308402777C2778378633 @default.
• W4308402777 hasConceptScore W4308402777C2780868878 @default.
• W4308402777 hasConceptScore W4308402777C55493867 @default.
• W4308402777 hasConceptScore W4308402777C71924100 @default.
• W4308402777 hasConceptScore W4308402777C86803240 @default.
• W4308402777 hasConceptScore W4308402777C90924648 @default.
• W4308402777 hasLocation W43084027771 @default.
• W4308402777 hasOpenAccess W4308402777 @default.
• W4308402777 hasPrimaryLocation W43084027771 @default.
• W4308402777 hasRelatedWork W1967595645 @default.
• W4308402777 hasRelatedWork W1988201115 @default.
• W4308402777 hasRelatedWork W2151861625 @default.
• W4308402777 hasRelatedWork W2172043331 @default.
• W4308402777 hasRelatedWork W2246406220 @default.
• W4308402777 hasRelatedWork W2352933428 @default.
• W4308402777 hasRelatedWork W2380647059 @default.
• W4308402777 hasRelatedWork W2389655874 @default.
• W4308402777 hasRelatedWork W2417323613 @default.
• W4308402777 hasRelatedWork W4256008481 @default.
• W4308402777 isParatext "false" @default.
• W4308402777 isRetracted "false" @default.
• W4308402777 workType "article" @default.